Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP321499.RAbUH_66lPBgWOOSjd78T-y_2C2Hy0RG14aIaVEtDJDYc130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321499.RAbUH_66lPBgWOOSjd78T-y_2C2Hy0RG14aIaVEtDJDYc130_provenance.
• NP394925.RA2GqaXYYNWnZB0ujvF3R1oNzpUqtUPBdhCEKrrEMM310130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP394925.RA2GqaXYYNWnZB0ujvF3R1oNzpUqtUPBdhCEKrrEMM310130_provenance.
• NP524039.RACryOlQyFMDsLuGkB9d220z9Mwu4lTZkR1w4weKm3agQ130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP524039.RACryOlQyFMDsLuGkB9d220z9Mwu4lTZkR1w4weKm3agQ130_provenance.
• NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP513912.RAncrV8n3WGiQ9iRxwHwX_nF2e7DMSlQu40lY9-oAqitI130_provenance.
• NP517326.RAk5DR4NVnXZrJM3wVmcuBGzf4Sn5WjBZYliYQWmGG6kU130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP517326.RAk5DR4NVnXZrJM3wVmcuBGzf4Sn5WjBZYliYQWmGG6kU130_provenance.
• NP878621.RAbJsIwN2UcUczapOTaa_HJVxMKqT7s7Y0lTSYH4MU0_g130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878621.RAbJsIwN2UcUczapOTaa_HJVxMKqT7s7Y0lTSYH4MU0_g130_provenance.
• NP526005.RAfP5xiRfSRwSM1dMfAvm3fq8QE5tcgSFvPgf6-k94nPo130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526005.RAfP5xiRfSRwSM1dMfAvm3fq8QE5tcgSFvPgf6-k94nPo130_provenance.
• NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613512.RAStJ22EPnbWiStOnPQ5J_1QSxbh-CTGDTW5lcnSenueY130_provenance.
• NP613875.RAVe95vU1QyRT4UwtqqDyHFdChNTWxAD7yxCY_5SWs8YE130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613875.RAVe95vU1QyRT4UwtqqDyHFdChNTWxAD7yxCY_5SWs8YE130_provenance.
• NP623712.RAHdTGiAKIC21FptfHjIzq04Rk1y3azfU9QrFmYeJipKk130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623712.RAHdTGiAKIC21FptfHjIzq04Rk1y3azfU9QrFmYeJipKk130_provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP899431.RARJLNqdG0NA2Wc6hFrG8J7OJYeZUxc9IdN7Bm2KWHc34130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899431.RARJLNqdG0NA2Wc6hFrG8J7OJYeZUxc9IdN7Bm2KWHc34130_provenance.
• NP899434.RAdTjhNx6Q9XWlfxqMRwsDLuWzFGccnLEwjb48nVBwXXI130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899434.RAdTjhNx6Q9XWlfxqMRwsDLuWzFGccnLEwjb48nVBwXXI130_provenance.
• NP899437.RAblEjTohonoSxlgkANS22US-ZKDTYegq80YOwFx76Bak130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899437.RAblEjTohonoSxlgkANS22US-ZKDTYegq80YOwFx76Bak130_provenance.
• NP525252.RApyVjYw2bEG1DfBYXp01XP1ygCXuwdPdwM5MBrCkx448130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525252.RApyVjYw2bEG1DfBYXp01XP1ygCXuwdPdwM5MBrCkx448130_provenance.
• NP613961.RABXV_jj_Qb6H7AbOrud5wyMoo4Hhfxdn6iIbpMLQrIqw130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613961.RABXV_jj_Qb6H7AbOrud5wyMoo4Hhfxdn6iIbpMLQrIqw130_provenance.
• NP526079.RAqFcmd9h9suJnHJtyPuNYih07kJAX7A2L8rA6oi8cs2Y130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526079.RAqFcmd9h9suJnHJtyPuNYih07kJAX7A2L8rA6oi8cs2Y130_provenance.
• NP899432.RAizTTkPP3SnRc3__MQ5jf5ESNDv58t_ARB0TR3f7LHfQ130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899432.RAizTTkPP3SnRc3__MQ5jf5ESNDv58t_ARB0TR3f7LHfQ130_provenance.
• NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613714.RAH2P5Q6kLnn4TJmHyI78trjdpOX52EaP5J3KGhgALHxE130_provenance.
• NP613919.RAx3-jgMCMipnN9ixnLWBC7Aq2efAnxm4UHtpZj50JSV8130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP613919.RAx3-jgMCMipnN9ixnLWBC7Aq2efAnxm4UHtpZj50JSV8130_provenance.
• NP899433.RAEkkKzxARCDm1qF6J_0ptkZPczKpeDbXUVDleE8rjO0k130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899433.RAEkkKzxARCDm1qF6J_0ptkZPczKpeDbXUVDleE8rjO0k130_provenance.
• NP899438.RAILsgZy3LuR53Ao4U9TE2RmgGo-ASj3Pg8KakZPoBKdQ130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899438.RAILsgZy3LuR53Ao4U9TE2RmgGo-ASj3Pg8KakZPoBKdQ130_provenance.
• NP899435.RAwZcr6DOZZ-b-QEnkVcQjPen8AQO-riL-dyCan9P-wE4130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899435.RAwZcr6DOZZ-b-QEnkVcQjPen8AQO-riL-dyCan9P-wE4130_provenance.
• NP899436.RA_zYkQvESlrOAqxAT_hx8z-5bFMNZEJphYrRRt0_4ygM130_assertion description "[Imatinib is effective in patients with increased mast cells and eosinophils associated with FIP1L1/PDGFRA+ (e.g., myeloid neoplasm with eosinophilia and rearrangement of PDGFRA) or rare patients with SM associated with KIT mutations outside of exon 17.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899436.RA_zYkQvESlrOAqxAT_hx8z-5bFMNZEJphYrRRt0_4ygM130_provenance.